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Summary
the authors present the case of a woman in the seventh 
decade of life with medical history of: left nephrectomy 
for renal tuberculosis and non-Hodgkin’s lymphoma 
treated with chemotherapy (Qt) and radiotherapy. she 
presented with a 2-month history of non-tender, left 
inguinal lymph node enlargement. positron emission 
tomography (pet)—Ct —scanshowed hypermetabolic 
inguinal and retroperitoneal lymphadenopathies, 
no primary tumour. on the second dermatological 
examination a pink, 2 cm plaque on the anterior left 
knee was noted. the histopathological analysis revealed 
Merkel cell carcinoma. the patient underwent two lines 
of systemic Qt, with life-threatening toxicities limiting 
treatment. Followed overwhelming disease progression 
with lymphoedema and numerous skin metastases in 
the left lower limb. the patient received palliative care 
until death. the rare incidence of such neoplasia and its 
uncommon clinical presentation justifies reporting this 
case and highlights the importance of multidisciplinary 
teams in the management of cancer patients.
BaCkground
This uncommon clinical presentation of Merkel cell 
carcinoma (MCC) in addition to its rare incidence 
justifies the utmost importance of publishing the 
case.
As more cases of unknown primary MCC 
(UPMCC) are reported in the literature, further 
characterisation of the tumour and determination 
of prognostic factors will become possible through 
combined analysis of these cases.
CaSe preSenTaTion
We present a case of a woman in the seventh decade 
of life with medical history of: left nephrectomy 
for renal tuberculosis in the third decade of life, 
and non-Hodgkin’s lymphoma of the right breast 
treated with chemotherapy (QT) and radiotherapy 
(RT) 12 years beforehand. The presenting feature 
was a 2-month history of non-tender, left inguinal 
lymph node (LN) enlargement (figure 1). An ultra-
sound-guided biopsy revealed LN metastasis of a 
carcinoma with neuroendocrine differentiation and 
high proliferative index—approximately 100%. 
(figure 2). On the first dermatological examination 
(April) no mucocutaneous suspicious lesions were 
found. The CT scan found large, conglomerate 
LN on the left inguinal and obturator basins. The 
PET-CT scan showed hypermetabolic inguinal and 
retroperitoneal lymphadenopathies but no primary 
tumour (figure 3). RT was done to the inguinal 
nodes with good response. On the second derma-
tological examination (4 months later, in August), 
a non-tender, pink, infiltrated, 2 cm plaque on the 
anterior surface of the left knee was found (figure 4). 
The histopathological findings of a biopsy of the 
lesion were compatible with metastases of an MCC 
of unknown primary location (figure 5).
ouTCome and follow-up
At this point, the patient begun systemic QT. 
The first line was cisplatin and etoposide with 
figure 1 Non-tender, left inguinal lymph node 
enlargement at presentation (April 2015).
figure 2 Histopathological findings in   ultrasound-
guided biopsy of left inguinal adenopathy: lymph 
node metastasis of a carcinoma with neuroendocrine 
differentiation (CK20+, synaptophysin+, CK7−, 
E-cadherin+) and high proliferative index (Ki-67 
approximately 100%).
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remarkable clinical and imaging response, but grade 3 kidney 
failure. This lead to changing to a second line (topotecan) with 
also clinical stable disease response, but grade 3 pancytopenia. 
These life-threatening toxicities limited treatment in both QT 
attempts. Overwhelming disease progression followed treatment 
suspension, with lymphoedema and numerous skin metastases 
on the left lower limb (figure 6). The patient received palliative 
care until death.
diSCuSSion
Knowledge regarding UPMCC is limited. It is still unclear 
whether its origin represents regional nodal involvement from 
an undetected and spontaneously regressed MCC, or a de novo 
development on the LN itself.
As MCC is such a rare and a challenging disease, treatment 
approaches should always be discussed in a multidisciplinary 
team and considered individually, in light the existing evidence 
combined with a reference centre expertise. The case reported by 
Muus Steffensen S et al is a good example of a patient with MCC 
treated with multimodal approaches (in this case, conservative 
surgery and adjuvant RT) allowing a combination of patient’s 
preferences, available treatments and evidence.1
Similarly to this case, in literature we found that a substan-
tial number of patients with UPMCC have a positive oncologic 
history.2 As its natural history is unpredictable, a multidisci-
plinary consultation at a centre with significant MCC expertise, 
including dermatology, medical oncology, radiation oncology 
and surgery, is in the best interest of the patient.3 4 UPMCC is 
probably best treated as stage III/IV MCC.5
There are recent studies that have shown that UPMCC have 
an improved survival outcome. However, there are limited 
evidence to support that fact2 6 7. In our case, the patient did 
not have sustained response to the treatment and overwhelming 
disease progression was seen.
Until 2016, before the introduction of immunotherapy, the 
most common treatments for metastatic MCC were chemother-
apeutic regimens often used for other small-cell carcinomas. 
These include platinum-based regimens, etoposide, taxanes and 
anthracyclines, either alone or in various combinations.8 These 
treatments led to clinically meaningful responses in a subset 
of patients; however, these responses were short-lived, as we 
demonstrated in our clinical case.
Histopathological characterisation could have helped to 
direct the treatment in this specific case. Striking data indicate 
that checkpoint inhibitors, antibodies targeting the inhibitory 
programmed cell death protein 1 (PD-1) receptor or its ligand 
(PD-L1), are effective in MCC. This suggests MCC is a highly 
immunosensitive malignancy. In 2017, Avelumab became the 
first drug approved by the US Food and Drug Administration 
for MCC. Pembrolizumab and nivolumab have shown similar 
efficacy in metastatic disease, and their approval in this setting is 
a certainty. Although there are no head-to-head trials comparing 
checkpoint inhibitors with CT, the results of this new immuno-
therapy-based approach compare favourably with historical data 
for CT in advanced MCC, especially in terms of safety features 
and durability of response.9–11
figure 3 PET-CT scan (sagittal): large, hypermetabolic inguinal and 
retroperitoneal lymphadenopathies; no primary tumour identified.
figure 4 Non-tender, pink, infiltrated, 2 cm plaque on the anterior 
surface of the left knee (August 2015).
figure 5 Histopathological findings in skin lesion biopsy (left knee): 
dense nests and cords of atypical basaloid cells infiltrating the dermis 
and hypodermis, staining positive for CK20, CAM5.2 and neurofilaments 
in a paranuclear dot-like pattern, and negative for CK7, S100 and TTF-
1—findings compatible with Merkel cell carcinoma.
 on 24 F














3Barreira JV, et al. BMJ Case Rep 2019;12:e224834. doi:10.1136/bcr-2018-224834
rare disease
The rising role of systemic immunotherapy in cancer is illus-
trated in a case reported by O’Brien T et al.12 The rationale 
for immunotherapy in MCC is based on the aetiology of this 
disease. In 2008, Feng et al described an oncogenic Merkel cell 
polyomavirus, present in about 80% of MCC tumours. This 
polyomavirus creates a large T antigen that inactivates tumour 
suppressors p53 and retinoblastoma protein. This discovery not 
only identified a causative factor for MCC, but also suggested a 
role for immune evasion in MCC’s oncogenesis.13 14
Despite major advances in the understanding of the carcino-
genesis, biology and immunology of MCC, as well as the 
breakthrough in the therapy of advanced-stage disease using 
immune-checkpoint inhibitors, much work remains. Further 
characterisation of this tumour is crucial for determining prog-
nostic factors and defining optimal treatment. Ongoing clin-
ical trials of immune-checkpoint inhibitors for MCC combine 
multiple treatment strategies to avoid or to overcome immune 
escape mechanisms.15
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figure 6 Disease progression after therapy discontinuation: (A) Emergence of skin metastases in the left inner thigh weeks after stopping 
radiotherapy to the inguinal basin (September 2015). (B,C) Numerous skin metastases and lymphoedema in the left lower limb after discontinuation 
of chemotherapy (March 2016).
learning points
 ► Merkel cell carcinoma (MCC) is an uncommon and highly 
aggressive cutaneous neoplasm with neuroendocrine 
differentiation.
 ► Although MCC typically presents as a rapidly growing 
asymptomatic skin nodule, some rare patients have nodal 
presentation with no identified primary tumour.
 ► By reporting the case of an advanced MCC presenting 
with extensive lymph node involvement prior to cutaneous 
manifestations, the authors aim to discuss this rare form of 
disease and highlight the importance of multidisciplinary 
teams in the management of cancer patients. As new data 
emerge about immunotherapies targeting the programmed 
cell death protein 1/ligand (PD-L1) pathway, the potential 
expression of PD-L1 in the MCC tumour microenvironment is 
of increasing interest.
 ► Combined analysis may also permit the definition of optimal 
treatment considering the rarity of this tumour.
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